BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chu JN, Choi J, Tramontano A, Morse C, Forcione D, Nishioka NS, Abrams JA, Rubenstein JH, Kong CY, Inadomi JM, Hur C. Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clin Gastroenterol Hepatol 2018; 16: 392-400. e7. [PMID: 29079222 DOI: 10.1016/j.cgh.2017.10.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Reddy CA, Tavakkoli A, Chen VL, Korsnes S, Bedi AO, Carrott PW, Chang AC, Lagisetty KH, Kwon RS, Elmunzer BJ, Orringer MB, Piraka C, Prabhu A, Reddy RM, Wamsteker E, Rubenstein JH. Long-Term Quality of Life Following Endoscopic Therapy Compared to Esophagectomy for Neoplastic Barrett's Esophagus. Dig Dis Sci 2021;66:1580-7. [PMID: 32519141 DOI: 10.1007/s10620-020-06377-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Molena D, DeMeester SR. Response. Gastrointest Endosc 2021;93:284-5. [PMID: 33353636 DOI: 10.1016/j.gie.2020.09.043] [Reference Citation Analysis]
3 Otaki F, Ma GK, Krigel A, Dierkhising RA, Lewis JT, Blevins CH, Gopalakrishnan NP, Ravindran A, Johnson ML, Leggett CL, Wigle D, Wang KK, Falk GW, Abrams JA, Nakagawa H, Rustgi AK, Wang TC, Lightdale CJ, Ginsberg GG, Iyer PG. Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Gastrointest Endosc 2020;92:31-39.e1. [PMID: 31953189 DOI: 10.1016/j.gie.2020.01.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
4 Kumble LD, Silver E, Oh A, Abrams JA, Sonett JR, Hur C. Treatment of early stage (T1) esophageal adenocarcinoma: Personalizing the best therapy choice. World J Meta-Anal 2019; 7(9): 406-417 [DOI: 10.13105/wjma.v7.i9.406] [Reference Citation Analysis]
5 Jiang KY, Huang H, Chen WY, Yan HJ, Wei ZT, Wang XW, Li HX, Zheng XY, Tian D. Risk factors for lymph node metastasis in T1 esophageal squamous cell carcinoma: A systematic review and meta-analysis. World J Gastroenterol 2021; 27(8): 737-750 [PMID: 33716451 DOI: 10.3748/wjg.v27.i8.737] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Scholte M, Rovers MM, Grutters JPC. The Use of Decision Analytic Modeling in the Evaluation of Surgical Innovations: A Scoping Review. Value Health 2021;24:884-900. [PMID: 34119087 DOI: 10.1016/j.jval.2020.11.020] [Reference Citation Analysis]
7 Daroudi R, Nahvijou A, Arab M, Faramarzi A, Kalaghchi B, Sari AA, Javan-noughabi J. A cost-effectiveness modeling study of treatment interventions for stage I to III esophageal squamous cell carcinoma. Cost Eff Resour Alloc 2022;20. [DOI: 10.1186/s12962-022-00352-5] [Reference Citation Analysis]
8 Moreno AC, Zhang N, Verma V, Giordano SH, Lin SH. Treatment disparities affect outcomes for patients with stage I esophageal cancer: a national cancer data base analysis. J Gastrointest Oncol 2019;10:74-84. [PMID: 30788162 DOI: 10.21037/jgo.2018.10.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Badgery H, Read M, Winter NN, Taylor ACF, Hii MW. The role of esophagectomy in the management of Barrett's esophagus with high-grade dysplasia. Ann N Y Acad Sci 2020;1481:72-89. [PMID: 32812261 DOI: 10.1111/nyas.14439] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Rubenstein JH, Inadomi JM. Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am 2021;31:77-90. [PMID: 33213801 DOI: 10.1016/j.giec.2020.08.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]